Pfizer Inc. has moved a step closer to reshaping the treatment paradigm for one of hemophilia’s most challenging patient subgroups. The company’s investigational therapy HYMPAVZI (marstacimab) demonstrated a 93 percent reduction in bleeding episodes in patients with hemophilia A or B who have developed inhibitors, according to data presented at the 67th American Society of Hematology Annual Meeting and simultaneously published in Blood. This population, long underserved by conventional treatment options, may now be on the verge of receiving a subcutaneous, once-weekly alternative that eliminates the need for factor replacement or bypassing agents.
The BASIS Phase 3 study, which formed the basis for HYMPAVZI’s regulatory filings, marks the first time an anti-tissue factor pathway inhibitor (anti-TFPI) therapy has shown superiority in a head-to-head setting against on-demand intravenous treatments. These findings elevate HYMPAVZI from promising to potentially practice-changing, especially as Pfizer seeks to extend its indication into both hemophilia A and hemophilia B with inhibitors.
While existing treatment options like emicizumab (Hemlibra) have already transformed care for patients with hemophilia A, a comparable biologic for patients with hemophilia B and inhibitors has remained elusive. HYMPAVZI’s emergence could fill that gap and introduce an entirely new class of prophylactic therapy for inhibitor-positive hemophilia.
How do anti-TFPI drugs work in patients with inhibitor-positive hemophilia?
Unlike traditional therapies that replace missing clotting factors VIII or IX, anti-TFPI drugs work by targeting natural anticoagulant mechanisms in the body. Tissue factor pathway inhibitor is a protein that regulates the initiation of clot formation. In patients with hemophilia A or B, this regulation often becomes unbalanced, especially when inhibitors neutralize replacement therapies.
HYMPAVZI specifically binds to the Kunitz 2 domain of TFPI. This interaction prevents TFPI from inhibiting activated factor X, allowing for improved thrombin generation and clot stability. This mechanism bypasses the need for clotting factor replacement, making the therapy particularly relevant for patients whose immune systems block factor VIII or IX altogether.
The subcutaneous delivery and weekly dosing schedule also offer significant advantages over intravenous bypassing agents, which require frequent hospital visits, complex preparation, and have variable clinical response. In this context, HYMPAVZI is designed to provide both a mechanistic and logistical upgrade over current standards.
What makes HYMPAVZI’s Phase 3 results a potential turning point for this patient group?
The BASIS study enrolled 48 adolescents and adults with severe hemophilia A or moderately severe to severe hemophilia B who had developed inhibitors. Participants were first treated for six months using on-demand intravenous bypassing agents, then transitioned to a 12-month period of weekly subcutaneous injections of HYMPAVZI.
The data showed a dramatic reduction in mean treated annualized bleeding rate, dropping from 19.78 events per year to just 1.39 under HYMPAVZI. The median bleeding rate fell to zero. These results were consistent across all patient demographics, including age and hemophilia type. This degree of reduction has rarely been seen in such a high-risk group.
HYMPAVZI also demonstrated clear superiority across all bleeding-related endpoints, including spontaneous bleeds, joint bleeds, and target joint bleeds. Secondary assessments indicated that the therapy improved patient-reported quality of life, with measurable gains in pain reduction, mobility, and emotional well-being. These improvements were quantified using the Haem-A-QoL and EQ-5D-5L scoring systems.
In terms of safety, no thromboembolic events or deaths were reported during the study period. The majority of adverse events were mild to moderate, including respiratory infections, elevated D-dimer levels, and headaches. One patient experienced a treatment-related skin rash which led to discontinuation but resolved without lasting effects.
How does HYMPAVZI compare to existing biologics and investigational agents?
The hemophilia treatment landscape has evolved dramatically in recent years with the approval of non-factor therapies like emicizumab, but those therapies have largely focused on hemophilia A. Emicizumab, a bispecific antibody that mimics factor VIII, has demonstrated clear benefit in patients with and without inhibitors. However, its mechanism makes it ineffective in hemophilia B. This leaves a significant treatment void for that population.
HYMPAVZI aims to close that gap. Unlike emicizumab, which is limited to hemophilia A, HYMPAVZI is being developed for both hemophilia A and hemophilia B with inhibitors. Its broad applicability gives it a competitive advantage, especially among biologics positioned for prophylactic use.
Other pipeline agents are also advancing in the non-factor space. Sanofi’s fitusiran uses RNA interference to reduce antithrombin levels and promote clotting. Novo Nordisk’s concizumab, like HYMPAVZI, is an anti-TFPI antibody but differs in binding domain and half-life. Both therapies show promise but are at varying stages of regulatory review and safety evaluation.
What sets HYMPAVZI apart is not just its target mechanism, but also its delivery format. The use of a once-weekly, prefilled autoinjector may improve adherence and convenience, particularly for pediatric and adolescent patients who struggle with IV access and complex regimens.
What is Pfizer’s strategy for regulatory approval and long-term adoption?
Pfizer has submitted the BASIS trial data to both the United States Food and Drug Administration and the European Medicines Agency. A regulatory decision is expected in 2026. In parallel, the company is conducting the BASIS KIDS study to evaluate HYMPAVZI in children under 18 with or without inhibitors, along with a long-term extension trial to monitor continued safety and efficacy.
These efforts suggest a deliberate strategy to position HYMPAVZI as a platform treatment across age groups and hemophilia types. By targeting both adults and pediatric patients, with or without inhibitors, Pfizer appears focused on capturing a significant share of the prophylactic market.
From a commercial standpoint, HYMPAVZI is expected to play a central role in Pfizer’s rare disease portfolio, particularly as the company shifts away from COVID-19 revenues and doubles down on specialty biologics. Analysts covering the company note that hemophilia remains a relatively under-penetrated segment with room for innovation, especially outside the United States and European Union where access to bypassing agents remains inconsistent.
What could anti-TFPI drugs mean for the future of hemophilia care guidelines?
The emergence of anti-TFPI therapies introduces the possibility of redefining what constitutes best practice in the management of inhibitor-positive hemophilia. These patients have historically required complex and expensive care. The shift to simpler, subcutaneous biologics could lead to changes in clinical guidelines that emphasize early prophylaxis over reactive care.
In addition, the introduction of anti-TFPI therapies could stimulate revisions in health technology assessments, particularly those evaluating quality-adjusted life years, hospitalization rates, and joint preservation. Payers may begin to recognize the long-term cost efficiency of these therapies despite their initial price point.
Subcutaneous biologics like HYMPAVZI also reduce the dependency on treatment infrastructure, making them attractive for implementation in lower-resource settings. If proven cost-effective, such therapies could expand access in regions where IV access and cold-chain logistics are significant barriers to care.
What are the key takeaways from HYMPAVZI’s clinical data and sector positioning?
Pfizer’s HYMPAVZI reduced annualized bleeding events by 93 percent in patients with hemophilia A or B with inhibitors. Median bleeding events fell to zero, signaling strong efficacy in a population with historically high treatment burden. HYMPAVZI also outperformed bypassing agents across all key secondary endpoints including spontaneous bleeds and joint bleeds, while improving quality-of-life scores in physical health and emotional domains. The therapy was generally well tolerated, with no thrombotic events or deaths reported. Regulatory submissions have been filed with both the United States Food and Drug Administration and the European Medicines Agency, and additional pediatric trials are underway.
HYMPAVZI is being positioned as the first subcutaneous biologic for both hemophilia A and B with inhibitors. This gives it a broader market scope than existing therapies like emicizumab, which are limited to hemophilia A. Pfizer’s development strategy includes pediatric expansion, long-term monitoring, and global access planning. Analysts expect HYMPAVZI to become a cornerstone of Pfizer’s rare disease portfolio and a disruptive force in the prophylactic treatment segment. If approved, HYMPAVZI could reshape global care guidelines, reduce treatment complexity, and improve long-term outcomes for one of the most vulnerable populations in hemophilia.
Can anti-TFPI drugs like HYMPAVZI reshape the standard of care in inhibitor-positive hemophilia? added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →